---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-251264"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:28:03.392084+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences CMO Michael Panzara resigns; Anne-Marie Li-Kwai-Cheung promoted to CDO

## Summary
- Michael Panzara, M.D., MPH, resigns as CMO effective Oct 14, 2022, to pursue another opportunity; no disagreement with company.
- Dr. Panzara will serve as consultant post-resignation for transition.
- Anne-Marie Li-Kwai-Cheung promoted to Chief Development Officer effective Oct 14, 2022.
- Li-Kwai-Cheung previously led Roche's tominersen Phase 3 program and Ocrevus global launch.
- She brings deep neurology and rare disease drug development experience to Wave.

## SEC filing metadata
- accession: 0001193125-22-251264
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/d392497d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-251264
- JSON: https://secwatch.observer/filing/0001193125-22-251264.json
- Plain text: https://secwatch.observer/filing/0001193125-22-251264.txt

## Key facts
- Executive change
  Michael Panzara resigned as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences Ltd..
  - Action: resigned
  - Role: Chief Medical Officer, Head of Therapeutics Discovery and Development
  source text: On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm
- Executive change
  Anne-Marie Li-Kwai-Cheung was appointed as Chief Development Officer at Wave Life Sciences Ltd..
  - Action: promoted
  - Role: Chief Development Officer
  source text: Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.